Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ESPR 
Esperion Therapeutics Inc (ESPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ESPR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.8
1 Year Target Price $5.8
| 2 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.92% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 445.59M USD | Price to earnings Ratio - | 1Y Target Price 5.8 |
Price to earnings Ratio - | 1Y Target Price 5.8 | ||
Volume (30-day avg) 7 | Beta 0.82 | 52 Weeks Range 0.69 - 3.94 | Updated Date 08/28/2025 |
52 Weeks Range 0.69 - 3.94 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.14 | Actual -0.02 |
Profitability
Profit Margin -38.8% | Operating Margin (TTM) 8.61% |
Management Effectiveness
Return on Assets (TTM) -6.34% | Return on Equity (TTM) -260.79% |
Valuation
Trailing PE - | Forward PE 1.34 | Enterprise Value 655742758 | Price to Sales(TTM) 1.66 |
Enterprise Value 655742758 | Price to Sales(TTM) 1.66 | ||
Enterprise Value to Revenue 2.45 | Enterprise Value to EBITDA 48.73 | Shares Outstanding 201623008 | Shares Floating 199759830 |
Shares Outstanding 201623008 | Shares Floating 199759830 | ||
Percent Insiders 0.56 | Percent Institutions 50.55 |
Upturn AI SWOT
Esperion Therapeutics Inc
Company Overview
History and Background
Esperion Therapeutics, Inc. was founded in 1998 and re-established in 2008. It focuses on developing and commercializing oral therapies for the treatment of elevated LDL-cholesterol.
Core Business Areas
- Cholesterol Management: Developing and commercializing therapies to lower LDL-cholesterol in patients with hyperlipidemia.
Leadership and Structure
The leadership team includes Sheldon Koenig (President & CEO) and other key executives. The organizational structure is typical of a publicly traded biopharmaceutical company.
Top Products and Market Share
Key Offerings
- NEXLETOL (bempedoic acid): An oral, once-daily non-statin LDL-cholesterol lowering medicine. Market share data is still developing; competing with statins and other lipid-lowering therapies from Amgen (AMGN), Regeneron (REGN), and Novartis (NVS). Sales are dependent on successful commercialization, which has been weak to date.
- NEXLIZET (bempedoic acid and ezetimibe): A fixed-dose combination of bempedoic acid and ezetimibe. Competing with other combination lipid-lowering therapies; competitors include those of Amgen (AMGN) and Regeneron (REGN). Sales are dependent on successful commercialization, which has been weak to date.
Market Dynamics
Industry Overview
The industry involves treatments for cardiovascular disease, specifically focusing on lipid management. There's a growing demand for non-statin therapies due to statin intolerance and limitations.
Positioning
Esperion aims to be a key player in non-statin LDL-cholesterol lowering therapies, especially for patients unable to tolerate statins.
Total Addressable Market (TAM)
The global dyslipidemia market is estimated to be in the tens of billions. Esperion is targeting a portion of this market with its non-statin options, focused on patients with statin intolerance or requiring additional LDL-C lowering.
Upturn SWOT Analysis
Strengths
- Novel non-statin LDL-cholesterol lowering therapies
- Oral, once-daily administration
- Addresses unmet need in statin-intolerant patients
Weaknesses
- Commercialization challenges and slow sales uptake
- Relatively small company size compared to competitors
- Dependence on successful marketing and sales efforts
Opportunities
- Expanding market for non-statin therapies
- Potential for partnerships and collaborations
- Further clinical development and label expansion
Threats
- Competition from established statins and other lipid-lowering drugs
- Pricing pressures from payers and insurers
- Clinical trial failures or safety concerns
Competitors and Market Share
Key Competitors
- AMGN
- REGN
- NVS
Competitive Landscape
Esperion faces stiff competition from established players with larger resources and broader portfolios. Its success depends on differentiating its products and overcoming commercialization hurdles.
Growth Trajectory and Initiatives
Historical Growth: Growth has been slow due to commercialization challenges.
Future Projections: Analyst projections depend on successful commercialization and market acceptance of NEXLETOL and NEXLIZET. Forecasts vary widely.
Recent Initiatives: Focus on increasing awareness, expanding market access, and pursuing strategic partnerships.
Summary
Esperion Therapeutics is a high-risk, high-reward biopharmaceutical company. Its novel therapies address an unmet need, but the company faces significant commercialization and financial challenges. Its future hinges on successfully penetrating the market and achieving profitability, which is not guaranteed. Close monitoring of sales and expenses is paramount.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Esperion Therapeutics Inc
Exchange NASDAQ | Headquaters Ann Arbor, MI, United States | ||
IPO Launch date 2013-06-26 | President, CEO & Director Mr. Sheldon L. Koenig | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 304 | Website https://www.esperion.com |
Full time employees 304 | Website https://www.esperion.com | ||
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.